Healthcare

Australia's biotechnology sector continues to evolve, with several companies marking significant milestones in their commercial and clinical journeys. Here's an overview of key ASX-listed biotech companies as of September 2025:

Regis Healthcare Limited (ASX:REG) has received supportive coverage from three brokers, each assigning a positive rating with price targets indicating meaningful upside from current market levels. The company, one of Australia’s leading residential aged care providers, continues to improve its operational and financial profile, …

Race Oncology Limited (ASX:RAC) saw its shares rise 8.33% to AUD 3.35 on 24 September 2025, following confirmation that the Republic of Korea Ministry of Food and Drug Safety (MFDS) has granted Investigational New Drug (IND) approval for RC220. The approval clears the way …

Telix Pharmaceuticals Limited (ASX:TLX) (NASDAQ:TLX) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix®, its next-generation PSMA-PET imaging agent for prostate cancer.

CLINUVEL Pharmaceuticals Limited (ASX:CUV) announced that the European Medicines Agency (EMA) has approved an updated label for its photoprotective drug SCENESSE® (afamelanotide), enabling adult erythropoietic protoporphyria (EPP) patients to receive implants every two months.

PYC Therapeutics Ltd (ASX:PYC) is an Australia-based biotechnology company developing precision genetic medicines, with an emphasis on peptide-conjugated oligonucleotide therapeutics for rare inherited diseases, notably in ophthalmology. As a pre-revenue clinical-stage business, the stock tends to trade on clinical milestones, funding conditions, and sector …

BCAL Diagnostics Limited (ASX:BDX) saw its shares rise 7.69% to trade at AUD 0.07 during the session on 18 September 2025. The increase followed the announcement of a new agreement with ClearNote Health Inc., a US-based precision diagnostics company.